Related Experiment Video
Updated: Jul 24, 2025

Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-19
Published on: May 25, 2022
Systemic inflammation index, disease severity, and mortality in patients with COVID-19: a systematic review and
Arduino A Mangoni1,2, Angelo Zinellu3
1Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.
Insights
The systemic inflammation index (SII) is a valuable biomarker for predicting severe COVID-19 outcomes. Higher SII levels on admission correlate with increased risk of severe disease and mortality in COVID-19 patients.
Area of Science:
- Hematology
- Infectious Diseases
- Biomarkers
Background:
- Systemic inflammation is linked to severe COVID-19 and mortality.
- The utility of specific inflammatory biomarkers for risk stratification in COVID-19 remains uncertain.
Approach:
- Conducted a systematic review and meta-analysis of 39 studies.
- Searched PubMed, Web of Science, and Scopus from December 2019 to March 2023.
- Assessed risk of bias and certainty of evidence using established methodologies.
Key Points:
- Patients with severe COVID-19 or non-survivors had significantly higher SII values on admission.
- SII was significantly associated with the risk of severe disease or death (OR=1.007, HR=1.99).
- Pooled sensitivity and specificity for severe disease or mortality were 0.71 and 0.71, respectively, with an AUC of 0.77.
Conclusions:
- The systemic inflammation index (SII) is a reliable inflammatory biomarker derived from routine hematological parameters.
- SII on admission is significantly associated with severe COVID-19 and mortality.
- SII can aid in the early risk stratification of COVID-19 patients.
Introduction:
An excessive systemic pro-inflammatory state increases the risk of severe disease and mortality in patients with coronavirus disease 2019 (COVID-19). However, there is uncertainty regarding whether specific biomarkers of inflammation can enhance risk stratification in this group. We conducted a systematic review and meta-analysis to investigate an emerging biomarker of systemic inflammation derived from routine hematological parameters, the systemic inflammation index (SII), in COVID-19 patients with different disease severity and survival status.
Methods:
A systematic literature search was conducted in PubMed, Web of Science, and Scopus, between the 1st of December 2019 and the 15th of March 2023. Risk of bias and certainty of evidence were assessed using the Joanna Briggs Institute Critical Appraisal Checklist and the Grades of Recommendation, Assessment, Development and Evaluation, respectively (PROSPERO registration number: CRD42023420517).
Results:
In 39 studies, patients with a severe disease or non-survivor status had significantly higher SII values on admission compared to patients with a non-severe disease or survivor status (standard mean difference (SMD)=0.91, 95% CI 0.75 to 1.06, p<0.001; moderate certainty of evidence). The SII was also significantly associated with the risk of severe disease or death in 10 studies reporting odds ratios (1.007, 95% CI 1.001 to 1.014, p=0.032; very low certainty of evidence) and in six studies reporting hazard ratios (1.99, 95% CI 1.01 to 3.92, p=0.047; very low certainty of evidence). Pooled sensitivity, specificity, and area under the curve for severe disease or mortality were 0.71 (95% CI 0.67 to 0.75), 0.71 (95% CI 0.64 to 0.77), and 0.77 (95% CI 0.73 to 0.80), respectively. In meta-regression, significant correlations were observed between the SMD and albumin, lactate dehydrogenase, creatinine, and D-dimer.
Discussion:
Our systematic review and meta-analysis has shown that the SII on admission is significantly associated with severe disease and mortality in patients with COVID-19. Therefore, this inflammatory biomarker derived from routine haematological parameters can be helpful for early risk stratification in this group.
Systematic Review Registration:
https://www.crd.york.ac.uk/PROSPERO, identifier CRD42023420517.
More Related Videos
07:48Intravenous Endotoxin Challenge in Healthy Humans: An Experimental Platform to Investigate and Modulate Systemic Inflammation
Published on: May 16, 2016
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
Related Concept Videos
Inflammatory Response I: Vascular and Cellular
Inflammation
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Myocarditis I: Introduction
Endocarditis II: Clinical Features of Infective Endocarditis
Pericarditis II: Clinical Features and Diagnostic Tests